Page 1 Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818 Nyrada 21 August 2026 Sydney, Australia Xolatryp® Demonstrates Significant and Sustained Cardioprotection in Preclinical Doxorubicin Study Highlights: • Xolatryp® ...
Xolatryp Demonstrates Cardioprotection in Preclinical Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Nyrada
- Nyrada Full Year Results FY2026
- Annual Report for year ended 30 June 2026
- Preliminary Final Report
- Appendix 4G and Corporate Governance Statement
- Change in substantial holding - M Azzi
Later from Nyrada
- Application for quotation of securities - NYR
- Cleansing Statement
- Investor Presentation- Evans&Partners Small Cap Healthcare
- Trading Halt
- Nyrada Successfully Raises AU$12.0 Million Via Placement
Follow Nyrada into a list and get an email when it puts out news.
Follow Nyrada